In March 2007, the pharmaceutical company Grifols signed an agreement to manage four new plasma collection centers in the U.S., which will add an additional 150,000 liters of plasma per year to the company’s two fractionation plants in Barcelona, Spain, and Los Angeles, CA.
Grifols manufactures several plasma-derived factor products to treat patients with bleeding disorders. Grifols’ current fractionation capacity is 3.6 million liters of plasma per year; overall capacity will increase by an additional 700,000 liters per year pending FDA approval of the company’s Los Angeles-based manufacturing facility, known as “MiniFrac.”
Grifols manufactures Alphanate®, a plasma-derived factor VIII/von Willebrand factor product for preventing and controlling bleeding in patients with hemophilia A or acquired factor VIII deficiency. It is also FDA-approved to treat specific patients with von Willebrand disease undergoing surgery or invasive procedures or in whom the synthetic hormone desmopressin is either ineffective or contraindicated. Grifols also produces AlphaNine®, a plasma-derived factor concentrate that prevents and controls bleeding in patients with hemophilia B; and Profilnine®, a plasma-derived factor concentrate for patients with factors II, VII or X deficiency.
Source: Grifols press release dated May 4, 2007